Description

Projekttitel: Impact of introduction of Entresto into clinical care in Sweden: patient selection, dosing, adherence, and outcomes. - A substudy of “Treatment of HFPEF and HFREF”; ethics approval number 2013/392-32”

Projektansvarig: Lars Lund

RiksSviktansvarig: Ulf Dahlström

EPN: 2016/2573-31 via KI OCH Novartis

Samkörning: 

Databas levererad: 

Status: Pågår

Projekt avslutat/databas återhämtad/destruerad: 

Publikationer: Poster på HFA

Impact of introduction of Entresto into clinical care in Sweden: patient selection, dosing, adherence, and outcomes.

- A substudy of “Treatment of HFPEF and HFREF”; ethics approval number 2013/392-32”